Location History:
- Sydney, AU (2013)
- Kansas City, MO (US) (2020)
Company Filing History:
2 out of 303 
2 out of 873 
Years Active: 2013-2020
Title: Antony A Cooper: Innovator in Alpha-Synuclein Research
Introduction
Antony A Cooper is a notable inventor based in Kansas City, MO (US). He has made significant contributions to the field of biomedical research, particularly in understanding and addressing synucleinopathies such as Parkinson's disease. With a total of 2 patents, his work focuses on innovative methods to modulate alpha-synuclein toxicity.
Latest Patents
Cooper's latest patents include compositions and methods for modulating the expression of genes involved in the trafficking from the endoplasmic reticulum (ER) to the Golgi apparatus. These compounds aim to inhibit alpha-synuclein mediated toxicity, which is crucial for treating or preventing conditions like Parkinson's disease. Additionally, he has disclosed methods for identifying inhibitors of alpha-synuclein mediated toxicity, further advancing the potential for therapeutic interventions.
Career Highlights
Throughout his career, Antony A Cooper has worked with prestigious institutions such as the Whitehead Institute for Biomedical Research and the University of Missouri. His research has been pivotal in exploring the mechanisms of neurodegenerative diseases and developing strategies to combat them.
Collaborations
Cooper has collaborated with esteemed colleagues, including Susan Lindquist and Aaron D Gitler. These partnerships have enriched his research and contributed to the advancement of knowledge in the field of synucleinopathies.
Conclusion
Antony A Cooper's innovative work in modulating alpha-synuclein toxicity represents a significant step forward in the fight against neurodegenerative diseases. His contributions continue to inspire further research and development in this critical area of biomedical science.